London, UK -- 05/21/08 --
SKYEPHARMA PLC - AGM RESULTS
LONDON, UK, 21 May 2008 - SkyePharma PLC (LSE: SKP) announces the
results of the voting by shareholders at the Annual General Meeting
held earlier today. All resolutions were passed on a show of hands.
Two copies of all resolutions passed will be submitted later
today to the UK Listing Authority's Document Viewing Facility which is
situated at.
25 The North Colonnade
Canary Wharf
London
E14 5HS
Full details of the proxy voting will be available on our website
(www.skyepharma.com) later today.
For further information please contact:
SkyePharma PLC
Frank Condella, Chief Executive Officer
Ken Cunningham, Chief Operating Officer +44 207 491 1777
Peter Grant, Finance Director
Financial Dynamics (London enquiries)
David Yates / Deborah Scott +44 207 831 3113
Trout Group (USA enquiries)
Christine Labaree / Seth Lewis +1 617 583 1308
About SkyePharma PLC
Using its proprietary drug delivery technologies, SkyePharma develops
new formulations of existing products to provide a clinical advantage
and life-cycle extension. The Group has twelve approved products in the
areas of oral, inhalation and topical delivery. The Group's products
are marketed throughout the world by leading pharmaceutical companies.
For more information, visit www.skyepharma.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
Contacts:
RNS
Customer
Services
0044-207797-4400
Email Contact
http://www.rns.com
